European Rare Disease M&A Activity in 2024

In 2024, the rare and orphan disease market has become a focal point for mergers and acquisitions (M&A) in the pharmaceutical industry.

Pharmaceutical companies are increasingly targeting this sector, driven by a combination of various incentives. This white paper explores the key factors driving M&A activity in the European rare disease space, and highlight notable deals and potential acquisition targets in 2024